Latest News for: nsclc

Edit

c-MET NSCLC Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 03 Apr 2025
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape.
Edit

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations versus osimertinib

Pharmiweb 31 Mar 2025
Amivantamab plus lazertinib received marketing authorisation in the UK for the first-line treatment of adult patients with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.2.
Edit

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

PR Newswire 26 Mar 2025
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC.
Edit

Biomednewsbreaks - Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings On Overcoming NSCLC Drug Resistance

MENA FN 21 Mar 2025
(MENAFN - Investor Brand Network) Kairos Pharma (NYSE American. KAPA) , a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakthrough in ... .
  • 1
×